我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
7
3 进行中
药物批准
245
批准总数
监管机构
5
监管机构数
成立时间
N/A
进行中（未招募）
2
28.6%
已完成
尚未招募
1
14.3%
招募中
EMA
European Medicines Agency
19
PHILIPPINES
Philippines FDA
6
SFDA
Saudi Food and Drug Authority
NPRA
National Pharmaceutical Regulatory Agency
CIMA_AEMPS
Spanish Agency for Medicines and Medical Devices
218
- The EMA's CHMP recommended 12 new medicines for approval at its September 14-17, 2026 meeting, alongside 11 therapeutic indication extensions and two biosimilars. - Povofortay (povorcitinib) became the first oral daily treatment recommended for adults with moderate to severe hidradenitis suppurativa refractory or intolerant to anti-TNF therapy. - Johnson & Johnson's Tecvayli (teclistamab) won support for earlier-line multiple myeloma use, with MajesTEC-3 data showing a 71% reduction in progression risk versus standard of care. - Two initial marketing applications were withdrawn, for apitegromab in 5q spinal muscular atrophy and trilaciclib in extensive-stage small-cell lung cancer, while three negative opinions entered re-examination.
